SCHEMBL3207909

SCHEMBL3207909

N=c1n(CCOc2ccccc2)c2ccccc2n1Cc1ccc(Br)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.68
LMNA P02545 7/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
KMT2A Q03164 4/20 0.55
TSHR P16473 3/20 0.55
MEN1 O00255 2/20 0.55
MAPT P10636 1/20 0.53
SLC5A2 P31639 2/20 0.52
HTT P42858 2/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NPSR1 Q6W5P4 3/20 0.50
MITF O75030 2/20 0.50
CXCR3 P49682 1/20 0.50
MAPK1 P28482 1/20 0.50
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49
ALDH1A1 P00352 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3205881 0.96 TP53 (0.74) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL2495808 0.94 MAPT (0.61) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL3205551 0.90 LMNA (0.67) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL2493856 0.88 MAPT (0.64) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL3188073 0.88 SLC5A2 (0.64) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL3194234 0.87 LMNA (0.65) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL2496996 0.85 MAPT (0.60) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL2495408 0.84 TP53 (0.67) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL3197522 0.84 TSHR (0.55) TP53LMNASMN1; SMN2KMT2ATSHR
SCHEMBL3194875 0.84 TP53 (0.56) TP53LMNASMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
EP-2041096-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS NeuroSearch AS (DK) 2009-04-01 EP disclosed
WO-2008003752-A1 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 TP53 4533/4885LMNA 2392/4885SMN1; SMN2 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.